Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1854MR)

This product GTTS-WQ1854MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1854MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13210MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ11831MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ5512MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ15832MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ13391MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ2309MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ866MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ7206MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW